Oliver Rausch PhD

Chief Scientific Officer, STORM Therapeutics

Oliver has overall responsibility for STORM’s biology platform and for the delivery of small molecule drugs from STORM’s drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial series A investment that launched STORM, and subsequently joined the company full time in October 2016. 

Prior to STORM, Oliver was Programme Director at the National Institute for Health Research (NIHR), where he led the Translational Research Partnerships (TRPs) initiative and other industry-focused programmes in experimental medicine and early drug development. He served as Vice President Biology at Cellzome until the company’s acquisition by GSK in 2012, and as Director of Biology at UCB Pharma until 2008. 

Oliver has over 25 years’ drug discovery experience in inflammation, neurology and oncology. He holds a degree in Biochemistry from the Free University Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.

Scroll to Top